8 Analysts Have This to Say About Century Therapeutics
Within the last quarter, Century Therapeutics (NASDAQ:IPSC) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
SVB Leerink Maintains Outperform on Century Therapeutics, Lowers Price Target to $14
SVB Leerink analyst Daina Graybosch maintains Century Therapeutics (NASDAQ:IPSC) with a Outperform and lowers the price target from $20 to $14.
HC Wainwright & Co. Maintains Buy on Century Therapeutics, Lowers Price Target to $19
HC Wainwright & Co. analyst Mitchell Kapoor maintains Century Therapeutics (NASDAQ:IPSC) with a Buy and lowers the price target from $25 to $19.
Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary
Pfizer (NYSE:PFE) announced positive top-line data from the Phase 3 clinical trial RENOIR investigating its bivalent RSV prefusion F…
FDA Announced Clearance To Century Therapeutics’ Allogeneic Cell Therapy Candidate Study
Century Therapeutics, Inc. (NASDAQ: IPSC) received ELiPSE-1 clinical study may proceed notification from the U.S. Food and Drug Administration (FDA) to assess CNTY-101 in patients with relapsed or refractory CD19 positive B-cell malignancies.